{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:48:59Z","timestamp":1785383339645,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.009","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T05:54:01Z","timestamp":1489125241000},"page":"93-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group"],"prefix":"10.1016","volume":"76","author":[{"given":"Johannes J.M.","family":"Kwakman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke H.J.","family":"Simkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter E.M.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.A.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.009_bib3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.009_bib4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.009_bib5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.009_bib6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2017.02.009_bib8","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.009_bib9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/bjc.1998.12","article-title":"The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate","volume":"77","author":"Arellano","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.02.009_bib10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.009_bib11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.009_bib12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.02.009_bib13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.009_bib14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"issue":"9980","key":"10.1016\/j.ejca.2017.02.009_bib15","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.009_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.009_bib18","first-page":"E27","article-title":"Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease","volume":"93","author":"Tsibiribi","year":"2006","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.009_bib20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.009_bib22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1742-1241.2007.01323.x","article-title":"5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring","volume":"61","author":"Yilmaz","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.009_bib23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3109\/0284186X.2012.762999","article-title":"Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer","volume":"52","author":"Kim","year":"2013","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.009_bib24","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.009_bib25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo\u00a0in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015","volume":"19","author":"K\u00f6hne","year":"2008","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.009_bib26","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdl179","article-title":"Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study","volume":"17","author":"Koopman","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.009_bib27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C","article-title":"The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy","volume":"71","author":"Robben","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.02.009_bib29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer a randomized phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.02.009_bib30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1470-2045(12)70363-7","article-title":"S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial","volume":"13","author":"Hong","year":"2012","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2017.02.009_bib31","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","article-title":"Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial","volume":"14","author":"Yamada","year":"2013","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2017.02.009_bib32","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1016\/j.ejca.2013.07.003","article-title":"Combination of cisplatin\/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin\/5-fluorouracil in the First-Line Advanced Gastric Cancer Study","volume":"49","author":"Ajani","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.02.009_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3640","article-title":"Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): the SALTO study of the Dutch Colorectal Cancer Group","volume":"34","author":"Punt","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.009_bib34","first-page":"941","article-title":"Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients","volume":"4","author":"Reigner","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.009_bib35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.bjc.6601224","article-title":"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil","volume":"89","author":"Yamada","year":"2003","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.009_bib36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10147-005-0516-7","article-title":"5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine","volume":"10","author":"Muneoka","year":"2005","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.009_bib28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T22:31:06Z","timestamp":1719095466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":36,"alternative-id":["S0959804917307347"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}